




REVIEW ARTICLE

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

Valentina Leta^{1,2} | Lisa Klingelhofer³  | Katherine Longardner⁴ | Marta Campagnolo⁵ | Hafize Çotur Levent⁶ | Federico Aureli⁷ | Vinod Metta^{1,8} | Roongroj Bhidayasiri^{9,10}  | Guy Chung-Faye^{1,8} | Cristian Falup-Pecurariu¹¹ | Fabrizio Stocchi¹²  | Peter Jenner¹³ | Tobias Warnecke¹⁴ | K. Ray Chaudhuri^{1,2} | International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group

¹Parkinson's Foundation Center of Excellence at King's College Hospital, London, UK

²Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London and National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre, Institute of Psychology, Psychiatry and Neurosciences, King's College London, London, UK

³Department of Neurology, Technical University Dresden, Dresden, Germany

⁴Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA

⁵Department of Neurosciences (DNS), University of Padova, Padova, Italy

⁶Afyonkarahisar State Hospital, Afyonkarahisar, Turkey

⁷Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy

⁸Kings College Hospital London, Dubai, United Arab Emirates

⁹Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

¹⁰Academy of Science, Royal Society of Thailand, Bangkok, Thailand

¹¹Department of Neurology, Transilvania University Brasov, Braşov, Romania

¹²Department of Neurology, University San Raffaele Roma and IRCCS San Raffaele Pisana, Rome, Italy

¹³Institute of Pharmaceutical Sciences, Faculty of Life Science and Medicine, King's College London, London, UK

¹⁴Department of Neurology and Neurorehabilitation, Klinikum Osnabrueck—Academic Teaching Hospital of the WWU Muenster, Osnabrueck, Germany

Correspondence

K Ray Chaudhuri, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, Cutcombe Road, London SE5 9RT, UK.

Email: ray.chaudhuri@kcl.ac.uk

Abstract

Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non-motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes play a part in the pathogenesis of these fluctuations, a range of barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non-optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, constipation, *Helicobacter pylori* infection, small intestinal bacterial overgrowth and gut dysbiosis. In addition, a protein-rich diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub-optimal levodopa response, 'delayed on' or 'no on' phenomena. In this narrative review, we provided an overview on the plethora of GI obstacles to levodopa transport and absorption

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

in PD and their implications on levodopa pharmacokinetics and development of motor fluctuations. In addition, management strategies to address GI dysfunction in PD are highlighted, including use of non-oral therapies to bypass the GI tract.

KEYWORDS

absorption, constipation, delayed gastric emptying, diet, dysphagia, levodopa, medication, microbiota, Parkinson's disease, pharmacokinetics, transport

INTRODUCTION

Seven decades after its introduction in clinical practice, levodopa still represents the gold standard for the symptomatic treatment of Parkinson's disease (PD), despite being far from a perfect drug [1]. Levodopa, the precursor of the neurotransmitter dopamine, is a large neutral amino acid (LNAA) that can bypass the blood-brain barrier and is converted into dopamine in the central nervous system (CNS) [2]. However, the limited oral bioavailability combined with the extremely short half-life make levodopa one of the most challenging molecules to control therapeutically. Referred to as the 'pharmacologist's nightmare', levodopa peripheral pharmacokinetics are complicated by (1) an extensive pre-systemic metabolism to dopamine in the gastrointestinal (GI) tract mediated by the enzymes L-amino acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT); (2) an absorption site limited to a short segment of the small intestine (duodenum and jejunum) and mediated by a transport system shared with and competed for by other LNAA; (3) a fast metabolism in the blood stream to dopamine or 3-O-methyldopa (3-OMD) by AADC or COMT enzymes [2]. Additional factors related to the GI tract morphology and functionality have emerged as possible negative influencers of levodopa transport and absorption. The latter is particularly relevant amongst people with PD (PwP), since this population often presents with concomitant GI dysfunction related to the disease itself (see Figure 1) [3].

Virtually the whole GI tract can be affected in PD, from the mouth to the rectum, and GI dysfunction is one of the most prominent aspects of PD at every disease stage, from prodromal to advanced [3,4]. Constipation, for instance, is one of the prodromal features of PD, preceding the onset of motor symptoms by up to 20 years, and is a risk factor for in life-manifest PD [5-7]. In addition, constipation is often a troublesome clinical manifestation which complicates management in all phases of the disease [8]. Recent studies have also highlighted the presence of alterations in the gut microbiota composition of PwP, although the clinical relevance needs to be further elucidated [9].

Together with the ongoing neurodegenerative processes, a range of barriers across the GI tract can play a role in the pathogenesis of motor and non-motor fluctuations in PwP [10,11], which occur almost inevitably once levodopa is started. Whilst the role of delayed gastric emptying in levodopa absorption has been reported by many researchers, a comprehensive review on how GI dysfunction, diet, comorbidity and medication intake can influence levodopa pharmacokinetics and contribute to the development of non-optimal levodopa response and fluctuations is lacking, and we aimed to address this in this narrative review. In addition, management strategies to address GI dysfunction in PD are highlighted, including the use of non-oral therapies to bypass the dysfunctional GI tract.




FIGURE 1 Postulated pathophysiological mechanisms underpinning gastrointestinal dysfunction in Parkinson's disease. Whilst some mechanisms are intrinsic to Parkinson's disease (blue arrows), others are extrinsic and not related to Parkinson's disease *per se* (red arrows).

FIGURE 2 Barriers to levodopa transport and absorption in the gastrointestinal tract. The figure shows barriers to levodopa pharmacokinetics categorised as absorption barriers (factors which affect levodopa absorption in the small intestine primarily) and transport barriers (factors which affect levodopa transport through the gastrointestinal tract primarily). Of note, transport barriers can ultimately alter levodopa absorption. 3-OMD, 3-O-methyldopa.




FIGURE 3 Absorption-related gastrointestinal obstacles. The figure shows the small intestine (lumen in white and villi in yellow) which is the site of oral levodopa absorption. A variety of barriers to levodopa absorption are illustrated including (1) human (1A) and bacterial (1B) AADC which prematurely decarboxylates levodopa to dopamine in the gastrointestinal tract; (2) COMT enzyme which metabolizes levodopa to 3-OMD in the gastrointestinal tract preventing its conversion to dopamine; (3) the potentially saturable LAAT system SLC7A9–SLC3A1 where levodopa competes with the amino acids arginine and leucine found in dietary protein. Whilst 3-OMD, which derives from levodopa metabolism by COMT enzyme, competes with levodopa for transport at the level of the blood–brain barrier, its role as a competitor at the level of the gastrointestinal tract is unclear. 3-OMD, 3-O-methyldopa; AADC, L-amino acid decarboxylase; COMT, catechol-O-methyltransferase; LAAT, large amino acid transporter.

The barriers: an overview

An oral levodopa tablet can encounter numerous challenges in the GI tract that can interfere with its transport, absorption or both (see Figure 2).

Transport-related obstacles

The transport of oral levodopa depends on several mechanisms, which can be disturbed in different segments of the GI tract. If taken as a tablet or capsule, levodopa must be transported through the mouth and swallowed after initiating the swallowing reflex.

The oral, pharyngeal and oesophageal parts of the swallowing process can be altered in PD [12]. In addition, delayed gastric emptying can slow the transport of levodopa from the oesophagus to the small intestine [13]. Within the intestine, impaired colonic motility can also prolong transportation time, causing 'slow transit' constipation and even resulting in faecal impaction [14–17]. Further, 'outlet' constipation, caused by anorectal dysfunction with defaecatory problems, occurs in up to two-thirds of PwP and may amplify slow transit constipation and indirectly delay the transport of levodopa [3,18]. Prolonged transit time of levodopa from the mouth to the small intestine can also facilitate the premature metabolism of levodopa in the GI tract, ultimately resulting in impaired absorption.

Absorption-related obstacles

Oral levodopa is administered combined with an AADC inhibitor (carbidopa or benserazide) to improve its efficacy and reduce peripheral side effects (e.g., nausea and vomiting). AADC is an enzyme distributed throughout the body that decarboxylates levodopa to dopamine in the brain and during its transportation through the GI tract and bloodstream (see [Figure 3](#)). The stomach can decarboxylate levodopa but has a limited capacity to absorb it [2], as the bulk of levodopa absorption occurs in the proximal small intestine [2]. Therefore, impaired gastric emptying delays levodopa delivery to the intestinal absorption sites, possibly increasing pre-systemic peripheral decarboxylation and resulting in reduced levodopa absorption [2]. In addition, recent evidence suggests that carbidopa or benserazide inhibit human AADC only, whilst bacterial forms of AADC are resistant to their effect [19]. As such, bacterial strains expressing AADC in the GI tract can further contribute to the premature metabolism of levodopa to dopamine in the intestinal lumen, which might also contribute to peripheral side effects.

Since levodopa is an LNAA, it shares its transport system with other LNAAs [20]. Physiologically, levodopa is absorbed rapidly in the proximal small intestine by a potentially saturable facilitated transport system. However, this is not the major LNAA transporter (LAAT) (SLC6A19), which seems to mediate levodopa transport from the plasma to the brain at the level of the blood-brain barrier, but a more restricted transporter system (SLC7A9-SLC3A1) with leucine and arginine as competitors [21,22]. Thus, the type and quantity of food and timing of meals can interfere with levodopa absorption (see [Figure 3](#)).

The COMT enzyme also plays an important part in levodopa pharmacokinetics and the latter is translated to clinical therapy with the use of COMT inhibitors (see [Figure 3](#)). COMT metabolises levodopa to 3-OMD, blocking its conversion to dopamine. There are two forms of COMT, which are expressed in the brain and other tissues of the body: (1) soluble COMT in the cytoplasm and (2) membrane-bound COMT, which is anchored to the inner side of the cell plasma membrane [23]. After oral levodopa administration, COMT activity in the GI tract converts a significant fraction of levodopa to 3-OMD, reducing the amount of levodopa available to the CNS. In addition, 3-OMD contributes to the total amount of LNAA, and competes with levodopa for absorption and transportation by the LAAT in the blood-brain barrier [24,25]. The amount of COMT activity varies between individuals based on different factors, including sex, race and various gene polymorphisms COMT [26–28]. Both peripherally acting COMT inhibitors (i.e., entacapone, opicapone) and CNS-active COMT inhibitors (i.e., tolcapone) are commercially available as oral tablets and are used for PD treatment [29] to prolong levodopa half-life and, subsequently, its bioavailability [30,31].

DYSPHAGIA

Dysphagia is often overlooked in PD and is common across all stages of the disease (prevalence varying from 18% to 100%) [3,32]. Both

dopaminergic and non-dopaminergic mechanisms contribute to the development of dysphagia [33] and disease severity, dementia, low body weight and drooling are all associated with swallowing disturbances in PD [34–36].

Dysphagia can affect the transport of oral levodopa tablets and contribute to the development of motor complications. Sato and colleagues described the case of a 69-year-old man with PD experiencing dysphagia as well as 'delayed on' and 'no on' phenomena [37]. Video fluorographic examination of swallowing during an 'off' episode revealed tongue hypokinesia with tablets retained in the epiglottic vallecula, which was associated with reduced levels of levodopa plasma concentration and a 'no on' phenomenon. After undergoing a 1-week tongue resistance exercise training regimen, the authors observed increased tongue mobility, faster tablet swallowing time, increased levels of levodopa plasma concentration, and reaching an 'on state' within 30min after tablet intake. This initial observation was further supported by a retrospective case study of 20 PwP. Flexible endoscopic evaluation of swallowing showed that residual drug in the pharynx was more likely in patients with 'delayed on' phenomenon (odds ratio [OR] 42.7, 95% confidence interval [CI] 1.89–962.9) [38]. A recent study assessed 66 PwP using flexible endoscopic evaluation of swallowing to detect dysphagia for medication, including the swallowing of two tablets and capsules of different sizes. A two-dimensional and graduated classification of dysphagia for medication was applied differentiating swallowing efficiency and swallowing safety. According to this classification, dysphagia for medication was present in nearly 70% of PwP and predicted motor complications according to the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part IV in a linear regression model (beta coefficient 0.5; $p = 0.006$). Capsules tended to be swallowed more efficiently compared to tablets, irrespective of size [39]. Further prospective and controlled studies are needed to confirm the role of dysphagia in levodopa transport and absorption.

Delayed gastric emptying

Delayed gastric emptying (DGE), or gastroparesis, is frequently observed in PwP, with an overall prevalence ranging from 35% to 100% [40]. Multifactorial in origin, DGE can be an intrinsic manifestation of PD or secondary to another medical comorbidity (e.g., diabetes mellitus, amyloidosis etc.), as well as iatrogenic (see [Figure S1](#)) [40,41]. Interestingly, levodopa itself can also induce DGE by binding gastric dopaminergic receptors in a dose-dependent manner [42–44].

Also, DGE is associated with delayed small bowel transit. In 65 PwP and various gastrointestinal symptoms, 35% exhibited gastroparesis by the wireless motility capsule study, 20% small bowel transit delay, whilst 8% had combined transit abnormalities suggestive of overlapping gastric and small bowel dysmotility [45].

Since levodopa is absorbed only in a small portion of the proximal intestine, DGE interferes with levodopa pharmacokinetics by prolonging the time that levodopa remains in the stomach and thus increasing the chance of AADC metabolising levodopa to dopamine

prematurely. Activation of gastric dopamine receptors promotes stomach relaxation and inhibits gastric motility. A standard levodopa/carbidopa tablet resides in the stomach for a relatively long period of time where it can be decarboxylated to form dopamine that could inhibit gastric motility. Differences in the pH and solidity of tablets may play a role for a more rapid and predictable transit of levodopa to the jejunum [46].

Some of the first evidences suggesting that DGE can interfere with levodopa absorption comes from a study of 11 PwP without unpredictable motor fluctuations who underwent a ^{13}C -octanoate breath test to measure gastric emptying and blood sampling to assess levodopa pharmacokinetics [47]. All PwP presented with DGE compared to controls (half gastric emptying time: PD 161 ± 37 min vs. controls 107 ± 10 min). Furthermore, lower levodopa absorption was observed in the PwP with slower gastric emptying [47]. This was further supported by Doi et al. in their case study of 31 PwP, where DGE, measured using the methods described above, was associated with delayed levodopa peak plasma concentration, with potential implications on levodopa delivery to the brain and motor response [48]. Djaldetti et al. showed that DGE, as measured by gastric scintigraphy, is more severe in PwP with motor fluctuations ('delayed on' or 'no on' phenomena) compared to those without fluctuations (gastric retention after 1 h: PD with fluctuations $77.4\% \pm 15.5\%$ vs. PD without fluctuations $64.0\% \pm 14.3\%$) [49].

Therefore, DGE negatively influences levodopa transport and absorption and contributes to the development of motor complications, such as 'delayed on' or 'dose failure' and potentially to medication overload.

Helicobacter pylori infection

Helicobacter pylori (HP) is a Gram-negative, microaerophilic bacterium that frequently infects the human GI tract, with a global prevalence ranging from 24% to 79% [50]. Recent meta-analyses confirmed that PwP have a higher prevalence of HP infection compared to persons without PD (OR 1.47, 95% CI 1.27–1.70) [51]. Furthermore, individuals with HP infection are more likely to develop PD compared to those without the infection (OR 1.59, 95% CI 1.37–1.85), suggesting a potential role for the infection in the pathogenesis of PD [52].

HP infection may represent an obstacle to levodopa transport and absorption due to a variety of mechanisms summarised in Figure S2.

According to a recent meta-analysis, PwP and HP infection have higher levodopa equivalent daily dose, worse motor symptoms severity, longer time to 'on' and reduced 'on' duration compared with those without HP [53]. Pierantozzi and colleagues were the first to demonstrate that HP infection can negatively impact levodopa pharmacokinetics in randomised controlled trials of PwP and motor complications [54–56] and showed that both the area under the curve of levodopa plasma concentration and the duration of clinical benefit can be augmented at 2 and 12 weeks after HP eradication (Table 1)

[56]. However, no statistically significant differences in levodopa absorption were observed in a case-control, cross-sectional study comparing levodopa pharmacokinetics-related outcomes in PwP with and without HP infection [57]. The results of this study suggest that changes in levodopa absorption after HP treatment could result from factors other than bacteria elimination, including reduced GI inflammation and use of antibiotics with prokinetic effect (i.e., macrolides) as part of the eradication therapy regimen [57]. Despite the unclear underlying mechanisms of action, a variety of open-label, case-control studies have shown the beneficial effect of HP eradication in PD on motor symptoms severity, time to 'on' and 'on' duration at up to 1 year after HP eradication. However, a recent single centre randomised, double-blind, placebo-controlled trial of PwP with HP infection failed to show reduction of motor symptoms severity and improved quality of life at 12 and 52 weeks [58].

Overall, despite the abundance of literature suggesting the possible negative impact of HP infection on levodopa absorption and motor symptoms, the only single centre randomised controlled trial so far showed no short-term or long-term clinical improvements after HP eradication. Further high-quality multicentre studies of enriched PD populations with motor fluctuations are required to evaluate whether HP screening is justified in PwP.

Diet

Levodopa bioavailability can be affected by various dietary factors, including meal timing and the type and quantity of food consumed (see Table 2). Levodopa transit time through the small intestine is around 3 h, and levodopa's half-life is short, ranging from 0.7 to 1.5 h [67,68]. Levodopa absorption is rapid, with time to peak plasma levodopa concentration ranging from 15 to 60 min [69,70]. Therefore, levodopa intake with respect to meal times is the easiest to influence in early to mid-stage PD, when patients typically take levodopa three to four times daily.

Meal timing

Several studies have demonstrated that the timing between levodopa and meal consumption can affect levodopa absorption and clinical effect (see Table 2) [70,71,76].

In general, the time to peak is shorter, peak plasma concentrations are higher, and the onset of clinical benefit is sooner when levodopa is taken in the fasting state. Thus, in patients taking oral levodopa, these studies suggest that taking medication on an empty stomach, adhering to a scheduled levodopa regimen and avoiding interactions with meals can improve the levodopa dose-response relationship to promote optimal absorption conditions in the GI tract and transportation conditions in the blood, leading to a shorter time to medication effect onset and longer duration of the clinical response.

TABLE 1 Original research studies investigating the impact of *Helicobacter pylori* infection on levodopa absorption, motor symptoms and complications in Parkinson's disease.

Study design	Study population	HP diagnosis	Main outcomes	Reference
Randomized, double-blind, placebo-controlled, parallel-group	34 patients with PD with HP infection and motor fluctuations on levodopa monotherapy	Gastric biopsy	HP eradication led to -↑ levodopa absorption (AUC) -↓ clinical disability (UPDRS-III) -↑ 'on-time' duration (UPDRS-III) -↓ gastritis/duodenitis scores at 2 weeks and 3 months after eradication	56
Double-blind, placebo-controlled, crossover group	7 patients with advanced PD and HP infection	Serum antibodies	HP eradication led to -↑ levodopa absorption (AUC) at 1 week after eradication	55
Open label, longitudinal, case-control	36 patients with PD, H&Y stage 2-4, disease duration ≥3 years	Serum antibodies	18 (50%) patients HP+ Eradication of HP led to -↓ motor dysfunction severity in on state (UPDRS-III) -↓ time to on -↑ on duration (diary) -↑ daily on time (diary) at 1 week after eradication	59
Case-control, cross-sectional	75 patients with PD, disease duration ≥4 years	¹³ C-labelled urea breath test	20 (27%) patients HP+ HP+ compared to HP- had -↓ severity of motor complications (UPDRS-IV) -↓ occurrence of WOF symptoms (WOF-9)	60
Retrospective survey	66 patients with PD	Gastric biopsy when positive screening test	HP eradication in 12 HP+ patients led to -↓ hypokinesia (gait test) over a median of 1.9 years	61
Open label, longitudinal	82 patients with PD	¹³ C-labelled urea breath test	27 (33%) patients HP+ Eradication of HP led to -↓ time to on (diary) -↑ on duration (diary) -↓ motor dysfunction severity (UPDRS-III) -↓ motor complications severity (UPDRS-IV) -↑ quality of life (PDQ-39) at 12 weeks post eradication	62
Case-control, cross-sectional	102 patients with PD	¹³ C-labelled urea breath test	33 (32%) patients HP+ HP+ compared to HP- had -↓ age -↓ motor dysfunction severity (UPDRS-III, pegboard and timed gait)	63

TABLE 1 (Continued)

Study design	Study population	HP diagnosis	Main outcomes	Reference
Open label, longitudinal, case-control	65 patients with PD and motor fluctuations	¹³ C-labelled urea breath test	35 (54%) patients HP+ compared to HP- had -↑ time to on (diary) -↓ on duration (diary) Eradication of HP led to -↓ time to on (diary) -↑ on duration (diary) at 12 weeks post eradication	64
Open label, longitudinal, case-control	94 patients with PD	¹³ C-labelled urea breath test	22 (23%) patients HP+ Eradication of HP led to -↓ motor dysfunction severity (UPDRS-III) at 1 year post eradication	65
Open label, longitudinal, case-control	40 patients with PD with motor fluctuations	¹³ C-labelled urea breath test	22 (55%) patients HP+ Eradication of HP led to -↓ daily off time (diary) -↑ WOF severity (WOF-9) -↓ GI symptoms (seven-item GI complaint score) at 6 weeks post eradication	66
Case-control, cross-sectional	73 patients with PD and motor fluctuations, H&Y stage 2-4	Stool antigen test	25 (34%) patients HP+ No differences in levodopa absorption between HP+ and HP- (AUC)	57
Randomised, double-blind, placebo-controlled, parallel-group	67 patients with PD and HP infection	¹³ C-labelled urea breath test and serum antibodies	Eradication of HP led to - no changes in motor severity (MDS-UPDRS-III) - no changes in motor complications severity (MDS-UPDRS-IV) - no changes in non-motor severity (MDS-UPDRS-I) - no changes in quality of life (PDQ-39) at 12 and 52 weeks after eradication	58

Abbreviations: AUC, area under the curve; H&Y, Hoehn and Yahr scale; HP, *Helicobacter pylori*; MDS, Movement Disorder Society; PD, Parkinson's disease; PDQ, Parkinson's Disease Questionnaire; UPDRS, Unified Parkinson's Disease Rating Scale; WOF, Wearing off.

TABLE 2 Original research studies investigating the impact of diet on levodopa absorption, motor symptoms and complications in Parkinson's disease.

Study design	Study population	Main outcomes	Reference
Meal timing			
Intra-subject randomized crossover	17 PD patients fasting after taking second daily oral dose of carbidopa/levodopa 1:10 ratio or benserazide/levodopa either 2 h before food or 30 min after food	When levodopa was taken after food: <ul style="list-style-type: none"> • ↑ triple the time to peak levodopa absorption, from 45 ± 23 min (fasting) to 134 ± 76 min • ↓ peak plasma concentrations (30% less) 	70
Intra-subject randomized crossover	8 PD patients taking controlled release carbidopa/levodopa 50/200mg in two separate sessions after fasting: 2 h before consuming a standard meal and 30 min after the standard meal	When levodopa was taken after food: <ul style="list-style-type: none"> - ↑ time to detectable plasma levodopa levels (mean 30 min to 75 min peak plasma levodopa concentrations were similar) - ↑ time to onset of clinical motor response (mean time to 67 min after fasting vs. 157 min after eating) ↓ response duration (mean 124 min after eating vs. 203 min before eating) 	71
Protein interaction			
Intra-subject crossover	5 PD patients with motor fluctuations in three situations: <ol style="list-style-type: none"> (1) 1.6 g/kg protein/day (high-protein diet) (2) 0.8 g/kg protein/day distributed throughout the day's 3 meals (3) 0.8 g/kg protein/day, with protein intake restricted to only the evening meal [66] 	All conditions demonstrated similar plasma levodopa levels (measured hourly) <p>After high-protein diet, patients had</p> <ul style="list-style-type: none"> - ↓ daily 'on' times - ↑ mean plasma LNAA levels 	72
Double-blind crossover	10 PD patients with unpredictable symptom fluctuations consumed milkshakes containing either <ol style="list-style-type: none"> (1) high protein (80g/day for men and 70g/day for women) or (2) low protein (50g/day for men and 40g/day for women), protein distributed throughout the day 	<ul style="list-style-type: none"> - Plasma levodopa levels were similar (measured in only 8 participants) regardless of diet - No difference in dyskinesias <p>During high-protein diet participants had:</p> <ul style="list-style-type: none"> - ↓ 'on' time (64% vs. 71%) 	73
Crossover; longitudinal observational	8 PD patients with motor fluctuations after consuming either 2 g/kg/day of protein vs. total 10 g protein/day; also 7 PD patients maintaining a low-protein diet (0.5 g/kg/day, divided) from 2 to 12 months	Higher protein consumption associated with <ul style="list-style-type: none"> - ↑ motor fluctuations <p>Participants that maintained a low-protein diet had</p> <ul style="list-style-type: none"> - ↓ levodopa dose requirements - ↓ motor fluctuations 	74
Crossover	9 PD patients with severe motor fluctuations after receiving oral levodopa and during continuous intravenous infusion; during fasting state and 15 min after eating	After eating, levodopa had <ul style="list-style-type: none"> - ↑ time to clinical effect - ↑ time peak plasma levels - ↓ peak plasma concentrations 	69
Retrospective observational	1047 PD patients; 877 taking levodopa; 52 with motor fluctuations	<ul style="list-style-type: none"> - 59% of participants reported protein interaction - 12% of those with motor fluctuations reported protein interaction <p>Average time to develop protein interaction ~13 years after start of motor symptoms, 8 years after starting levodopa</p>	75

Abbreviations: LNAA, large neutral amino acids; PD, Parkinson's disease.

Protein

Dietary protein can interfere with levodopa bioavailability and reduce the clinical response in PD for several reasons [77]. Protein can

delay gastric emptying [78]. Furthermore, LNAA in dietary proteins can hinder levodopa absorption in the small intestine and compete with levodopa transport across the blood-brain barrier [20]. A number of studies have investigated the effect of dietary protein on

levodopa response in PD, which are summarised in [Table 2](#). These studies show that meals containing higher proteins, and specifically LNAs, reduce levodopa clinical effect, whilst meals with less protein, especially when the protein is concentrated in the latter part of the day, can optimise levodopa effect. A study by Tsui et al. found that, in PwP with motor fluctuations, consuming a low-protein diet was associated with a trend toward better motor performance compared to a high-protein diet, although no difference in dyskinesias was observed between high- and low-protein diets [73]. The amount of dietary protein ingestion may affect the short-term and long-term therapeutic efficacy of levodopa, and PwP who are maintained on a low-protein diet for months may have improvement in motor fluctuations and require less levodopa to maintain optimal symptoms control [74].

Collectively, these findings support that dietary protein can affect levodopa's absorption and that LNA competition with levodopa for active transport is more problematic at the blood–brain barrier than in the intestine. Although these results suggest that following the World Health Organization's recommended dietary allowance of 0.75 g protein/kg body weight daily should not affect the levodopa dose–response [79], it is possible that lower daily protein consumption can improve clinical levodopa response and motor fluctuations in PD; however, a low-protein diet should not be attempted without the involvement of both a clinician and dietitian due to the risk of protein malnutrition.

Based on the available evidence, oral levodopa intake on an empty stomach (45–60 min before a meal) is recommended if tolerated (no nausea). In addition, avoiding dietary protein (dairy, nuts, meat, beans, seeds, whole grain) 30 min before or after levodopa intake is advisable.

Gut microbiota and small intestinal bacterial overgrowth

Over the last decade, the role of the gut microbiota, a network of resident bacteria, protozoa, fungi and viruses that live symbiotically within the GI tract, has been studied with increasing attention in PD [80]. Two recent meta-analyses have shown enrichment of specific bacteria (including *Akkermansia* and *Lactobacillus* genera) and depletion of short-chain fatty acid producing bacteria in PwP compared to healthy controls, resulting in a pro-inflammatory gut dysbiosis [9,81]. The latter has been suggested to play a potential role in the pathogenesis of PD.

The myriad of microorganisms duelling in the GI tract and their metabolic products can affect levodopa's absorption. According to preclinical evidence, bacterial strains expressing tyrosine decarboxylase (TDC) can prematurely decarboxylate levodopa to dopamine in the small intestine before it is absorbed, reducing the levels of bioavailable levodopa [19,82]. In stool samples of PwP, van Kessel et al. showed a positive association between the relative abundance of bacterial TDC gene and dopaminergic medication use and disease duration [83]. Another study showed that in the small intestine of

rats receiving oral levodopa/carbidopa, levodopa plasma levels were negatively associated with the abundance of bacterial TDC gene [19]. Thus, PwP who have high levels of these resident gut bacteria in the small intestine may require increased levodopa doses to achieve symptomatic benefit. However, a recent study on PwP on levodopa-carbidopa intestinal gel infusion found no association between the presence of TDC producing bacteria and levodopa plasma concentration [84].

Levodopa's absorption can also be influenced by the presence of small intestinal bacterial overgrowth (SIBO) which is defined as an increased concentration of bacteria above 10^5 colony-forming units/ml or the presence of unusual colonic-type bacteria in the small intestine. Like other disorders associated with abnormalities of GI motility (i.e., diabetes mellitus), an increased prevalence of SIBO has been reported in PwP (up to 55%) [85] compared to healthy subjects [86]. Common predisposing conditions for SIBO in PD include GI dysmotility, longer disease duration and proton pump inhibitor therapy. Moreover, a concomitant HP infection, frequently requiring prolonged proton pump inhibitor treatment and eventually favouring GI impaired motility, is an additional risk factor [85].

Small intestinal bacterial overgrowth has been associated with increased frequency of motor fluctuations, longer 'off' phases and suboptimal response to levodopa, resulting in worse motor function overall [86,87]. SIBO may be able to create and maintain an inflammatory environment in the intestinal mucosa that contributes to levodopa malabsorption. Moreover, SIBO eradication with antibiotic treatment such as rifaximin might improve motor performance in PD [88]. However, several studies have shown no changes in levodopa pharmacokinetic measurements after eradicating SIBO, suggesting that the underlying mechanism is probably multifactorial and highlighting the need for further research on the topic [82,88,89].

CONSTIPATION

Constipation has a prevalence of 20%–89% [3,34,90] and is up to six-fold more common amongst PwP than amongst age- and sex-matched controls [90,91]. In PD, constipation is mainly associated with impaired colonic motility leading to prolonged colonic transit times and clinically reflecting in slow transit constipation [16,17]. 'Outlet' constipation, caused by anorectal dysfunction with defaecatory problems, occurs in up to two-thirds of PwP but does not directly affect levodopa absorption and pharmacokinetics, respectively, although it can exacerbate slow transit constipation [3,18]. Slow intestinal transit contributes to a delay, reduction or even blockage of oral levodopa uptake, with potential delay or loss of effect (see [Figure S3](#)) [40,92]. Slow transit constipation can, indeed, exacerbate delayed gastric emptying via a cologastric brake/reflex (rectal distension may inhibit gastric emptying via neural and humoral components) [93,94], prolong oral levodopa transportation time and increase the chances for levodopa to be prematurely metabolised by AADC and COMT in the GI tract [47].

TABLE 3 Diagnostic and therapeutic management of gastrointestinal dysfunction in Parkinson's disease.

GI barrier	Objective diagnostic tests	Therapeutic strategies
Dysphagia	<ul style="list-style-type: none"> • Flexible endoscopic evaluation of swallowing (FEES) • Video fluoroscopic swallowing study (VFSS) 	<ul style="list-style-type: none"> • Maximize 'on' time with dopaminergic treatment • Swallow therapy from speech and language therapists including FEES assisted biofeedback • Expiratory muscle strength training • Gastrostomy for severe cases
Delayed gastric emptying	<ul style="list-style-type: none"> • ¹³C-octanoate breath test • Gastric scintigraphy • Ultrasonography • Electrogastrography • Magnetic resonance imaging • Wireless motility capsule 	<ul style="list-style-type: none"> • Dietary modifications (e.g., low-fat diet with small, frequent meals) • Peripheral dopamine blockers (domperidone) • Motilin receptor agonists (erythromycin or azithromycin) • Serotonin agonists (mosapride or prucalopride) • Cholinergic enhancers (bethanechol or pyridostigmine)
<i>Helicobacter pylori</i> infection	<ul style="list-style-type: none"> • Urea breath test • Stool antigen test • Serological tests • Endoscopic biopsy samples with histological analysis or rapid urease testing 	<ul style="list-style-type: none"> • 'Triple therapy', which includes a proton pump inhibitor and clarithromycin and amoxicillin or metronidazole
Small intestinal bacterial overgrowth	<ul style="list-style-type: none"> • Glucose or lactulose hydrogen breath tests • Jejunal aspirate 	<ul style="list-style-type: none"> • Eradication with rifaximin
Constipation	<ul style="list-style-type: none"> • CTT studies with radiopaque markers 	<ul style="list-style-type: none"> • Adequate fluid intake, increase dietary insoluble fibre • Regular physical activity • Probiotics and prebiotics • Osmotic laxatives (e.g., Macrogol, Movicol® or Miralax®) • Bulk laxatives (e.g., psyllium or linseed) • Stimulant laxatives (e.g., Bisacodyl) • Prokinetic agents (e.g., cisapride, mosapride, tegaserod) • Chloride channel activator (lubiprostone)

Abbreviations: CTT, colonic transit time; GI, gastrointestinal.





FIGURE 4 Enablers of intestinal levodopa absorption in Parkinson's disease. H. Pylori, *Helicobacter pylori*; SIBO, small intestinal bacterial overgrowth; TDC, tyrosine decarboxylase.

FIGURE 5 Pragmatic algorithm on how to tackle gastrointestinal barriers to levodopa transport and absorption in patients with Parkinson's disease and non-optimal oral levodopa response in clinical practice. It is envisaged that gut microbiota screening will shortly be included in clinical practice to identify the abundance of bacterial species able to metabolise levodopa in patients with PD with non-optimal levodopa response.



Although, to the best of our knowledge, there are no studies investigating the impact of constipation on levodopa pharmacokinetics in PD, it can be argued that slow transit constipation can impair levodopa transport and absorption and contribute to the development of motor complications such as severe 'off' periods.

Iatrogenic factors

Since levodopa's absorption occurs in a small portion of the intestine, any surgical procedure affecting the GI tract might influence levodopa pharmacokinetics. However, to the best of our knowledge, the possible role of GI surgery in affecting oral levodopa's absorption has not been systematically investigated. To date, only a few case reports and small case series exist, with controversial results [95–98].

Regarding medication, previous studies on both rats and humans showed that the concomitant administration of anticholinergic drugs whilst receiving levodopa may interfere with its GI absorption by delaying gastric emptying and inducing constipation [99]. Other substances affecting gastric motility may have a role in the pharmacokinetics of levodopa. For example, antacids initially favour levodopa transport and absorption by promoting gastric emptying [100]. However, their prolonged use leads to excessive neutralisation of gastric acidity, eventually reducing levodopa absorption. Additionally, antacids containing aluminium may also contribute to delayed gastric emptying as well as other drugs shown in Figure S1. Ferrous sulfate, a compound used to treat and prevent iron deficiency, may also interfere with levodopa pharmacokinetics by decreasing its absorption in the proximal small intestine [101].

Medical comorbidities

General medical conditions that primarily affect the absorption process—particularly those involving the bowel absorptive surface—should be considered as potential barriers to levodopa's absorption [102]. Despite being relatively common, their impact on levodopa pharmacokinetics has not been investigated, with only anecdotal evidence being available [103]. Short bowel syndrome secondary to intestinal resections, Crohn's disease, coeliac disease as well as radiation enteritis might represent obstacles to levodopa's absorption in PwP with non-optimal levodopa response.

Management strategies

Given the important influence of GI tract morphology and functionality on levodopa pharmacokinetics, it is crucial to evaluate the presence of GI barriers to levodopa transport and absorption in PwP presenting with poor levodopa response and motor complications, such as 'delayed on' and 'no on' phenomena. The concomitant presence of upper or lower GI symptoms may further indicate a possible underlying GI dysfunction and prime management strategies aimed at identifying and treating GI obstacles to levodopa transport and absorption (see Table 3); however, GI dysfunction in PD can often be asymptomatic, and the absence of GI-related symptoms should not automatically rule out its presence.

It is a common clinical practice to use the dispersible formulation of levodopa in PwP with GI symptoms and 'delayed on' episodes given the shorter time to peak of levodopa with the dispersible formulation compared with the standard form [104,105]. In addition, ascorbic acid intake combined with levodopa might improve the absorption of the latter [106,107]. These and other practical management strategies enabling intestinal levodopa absorption are summarised in Figure 4.

Once GI barriers have been identified, and if management strategies to address them have failed, clinicians should consider the use of non-oral therapeutic strategies for dopaminergic delivery to bypass the dysfunctional GI tract. Use of rotigotine transdermal patch and device-aided therapies such as apomorphine subcutaneous injection and infusion, levodopa-carbidopa intestinal gel (LCIG) infusion and deep brain stimulation (DBS) represent useful therapeutic options (see Figure 5). Other non-oral approved formulations and delivery systems include levodopa-carbidopa-entacapone intestinal infusion, sublingual apomorphine and inhaled levodopa. Of note, preliminary data suggest that use of rotigotine transdermal patch, LCIG infusion and DBS can also improve symptoms related to GI dysfunction in PwP [108–111].

CONCLUSION

Throughout its journey from the mouth to the brain, oral levodopa faces a multitude of obstacles in the GI tract, leading to alteration

of its pharmacokinetics, non-optimal levodopa response, and ultimately motor and non-motor fluctuations. Identification and management of GI barriers to levodopa transport and absorption should be integral to routine clinical practice in the management of PwP.

ACKNOWLEDGEMENTS

The views expressed are those of the authors and not necessarily those of the NHS, NIHR or Department of Health. The authors acknowledge the support of the IP-MDS Non-Motor Parkinson's Disease Study Group, the NIHR London South CRN Network and the NIHR BRC. This article represents independent collaborative research part funded by the NIHR BRC at South London and Maudsley NHS Foundation Trust and KCL. Figures 1, 2, 3 and S1 were created with BioRender.com.

FUNDING INFORMATION

The authors did not receive support from any organisation for the submitted work.

CONFLICT OF INTEREST STATEMENT

V.L. reports grants from Parkinson's UK and honoraria for sponsored symposium from UCB, Bial, Invisio, Profile, AbbVie and Britannia Pharmaceuticals, outside the submitted work. K.L.'s research is supported by NIH grants 1R21NS114784-01A1 and 1KL2TR001444. RB has royalties or licences with Springer Science+ Business Media (Humana Press) and John Wiley & Sons Inc., received consulting fees from H Lundbeck A/S, B.L.Hua Co. Ltd, Abbott Laboratories, Ipsen SA, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Co. Ltd, Otsuka Pharmaceutical Co. Ltd, and received payment or honoraria from the International Parkinson's and Movement Disorder Society and the Korean Movement Disorder Society. He has patents for a Parkinson's cup, Nocturnal Monitoring Device, Tremor Analysis Software and Device, and a Laser-guided Walking Stick as well as leadership of fiduciary roles in the International Parkinson and Movement Disorder Society, Chulalongkorn University, and the World Health Organization. C.F.P. received royalties from Elsevier, Springer Verlag, honoraria from AbbVie, International Parkinson Disease and Movement Disorders Society, outside of the present work. K.R.C. reports advisory boards for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; grants (Investigator Initiated) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, Bial; academic grants from EU, IMI EU, Horizon 2020, Parkinson's UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust, outside the submitted work.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Lisa Klingelhofer  <https://orcid.org/0000-0003-2037-6518>

Roongroj Bhidayasiri  <https://orcid.org/0000-0002-6901-2064>

Fabrizio Stocchi  <https://orcid.org/0000-0002-5763-0033>

REFERENCES

- Schapira AHV, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. *Eur J Neurol*. 2009;16(9):982-989. doi:10.1111/j.1468-1331.2009.02697.x
- Contin M, Martinelli P. Pharmacokinetics of levodopa. *J Neurol*. 2010;257(Suppl 2):S253-S261. doi:10.1007/s00415-010-5728-8
- Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Parkinsonism Relat Disord*. 2011;17(1):10-15. doi:10.1016/j.parkreldis.2010.08.003
- Metta V, Leta V, Mrudula KR, et al. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. *J Neurol*. 2022;269(3):1154-1163. doi:10.1007/s00415-021-10567-w
- Leta V, Urso D, Batzu L, et al. Constipation is associated with development of cognitive impairment in de novo Parkinson's disease: a longitudinal analysis of two international cohorts. *J Parkinsons Dis*. 2021;11(3):1209-1219. doi:10.3233/JPD-212570
- Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α -synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. *Ann Neurol*. 2016;79(6):940-949. doi:10.1002/ana.24648
- Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology*. 2001;57(3):456-462. doi:10.1212/wnl.57.3.456
- Stocchi F, Torti M. Constipation in Parkinson's disease. *Int Rev Neurobiol*. 2017;134:811-826. doi:10.1016/bs.irm.2017.06.003
- Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. *NPJ Park Dis*. 2021;7(1):27. doi:10.1038/s41531-021-00156-z
- Leta V, Jenner P, Chaudhuri KR, Antonini A. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? *An update Expert Opin Drug Saf*. 2019;18(12):1203-1218. doi:10.1080/14740338.2019.1681966
- Chaudhuri KR, Rizo A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? *J Neural Transm Vienna Austria*. 2013;120(9):1305-1320. doi:10.1007/s00702-013-0981-5
- Kalf JG, de Swart BJM, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord*. 2012;18(4):311-315. doi:10.1016/j.parkreldis.2011.11.006
- Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. *Mov Disord*. 2014;29(1):23-32. doi:10.1002/mds.25708
- Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. *Mov Disord*. 1991;6(2):151-156. doi:10.1002/mds.870060211
- Jost WH, Schrank B. Defecatory disorders in de novo parkinsonians—colonic transit and electromyogram of the external anal sphincter. *Wien Klin Wochenschr*. 1998;110(15):535-537.
- Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2003;74(2):268-272. doi:10.1136/jnnp.74.2.268
- Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. *Neurology*. 1992;42(4):726-732. doi:10.1212/wnl.42.4.726
- Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2000;68(6):768-770. doi:10.1136/jnnp.68.6.768
- van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. *Nat Commun*. 2019;10(1):310. doi:10.1038/s41467-019-08294-y
- Nutt JG, Fellman JH. Pharmacokinetics of levodopa. *Clin Neuropharmacol*. 1984;7(1):35-49. doi:10.1097/00002826-198403000-00002
- Lennernas H, Nilsson D, Aquilonius S, Ahrenstedt O, Knutson L, Paalzow L. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. *Br J Clin Pharmacol*. 1993;35(3):243-250. doi:10.1111/j.1365-2125.1993.tb05691.x
- Camargo SMR, Vuille-dit-Bille RN, Mariotta L, et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease. *J Pharmacol Exp Ther*. 2014;351(1):114-123. doi:10.1124/jpet.114.216317
- Finberg JPM. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. *J Neural Transm Vienna Austria*. 2019;126(4):433-448. doi:10.1007/s00702-018-1952-7
- Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. *Ann Neurol*. 1987;21(6):584-588. doi:10.1002/ana.410210610
- Müller T. Catechol-O-methyltransferase inhibitors in Parkinson's disease. *Drugs*. 2015;75(2):157-174. doi:10.1007/s40265-014-0343-0
- Kunugi H, Nanko S, Ueki A, et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. *Neurosci Lett*. 1997;221(2-3):202-204. doi:10.1016/s0304-3940(96)13289-4
- Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. *Hum Mol Genet*. 2005;14(1):135-143. doi:10.1093/hmg/ddi013
- Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? *Neurol Sci*. 2003;24(3):192-193. doi:10.1007/s10072-003-0125-z
- Männistö PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. *Br J Pharmacol*. 1992;105(3):569-574.
- Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. *Eur J Clin Pharmacol*. 2009;65(5):443-455. doi:10.1007/s00228-009-0622-y
- Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. *Neuropsychiatr Dis Treat*. 2008;4(1):39-47. doi:10.2147/ndt.s1660
- Bhidayasiri R, Phuenpathom W, Tan AH, et al. Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice—balancing pharmacological and non-pharmacological approaches. *Front Aging Neurosci*. 2022;14:979826. doi:10.3389/fnagi.2022.979826
- Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. *NPJ Park Dis*. 2022;8(1):31. doi:10.1038/s41531-022-00295-x
- Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. *Mov Disord*. 2009;24(11):1641-1649. doi:10.1002/mds.22643

35. Cereda E, Cilia R, Klersy C, et al. Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors. *Parkinsonism Relat Disord*. 2014;20(12):1382-1387. doi:10.1016/j.parkreldis.2014.09.031
36. van Wamelen DJ, Leta V, Johnson J, et al. Drooling in Parkinson's disease: prevalence and progression from the non-motor international longitudinal study. *Dysphagia*. 2020;35(6):955-961. doi:10.1007/s00455-020-10102-5
37. Sato H, Yamamoto T, Sato M, Furusawa Y, Murata M. Dysphagia causes symptom fluctuations after oral L-DOPA treatment in a patient with Parkinson disease. *Case Rep Neurol*. 2018;10(1):101-107. doi:10.1159/000488138
38. Fukae J, Fujioka S, Umemoto G, et al. Impact of residual drug in the pharynx on the delayed-on phenomenon in Parkinson's disease patients. *Mov Disord Clin Pract*. 2020;7(3):273-278. doi:10.1002/mdc3.12908
39. Labeit B, Berkovich E, Claus I, et al. Dysphagia for medication in Parkinson's disease. *NPJ Park Dis*. 2022;8(1):1-8. doi:10.1038/s41531-022-00421-9
40. Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. *Parkinsonism Relat Disord*. 2020;76:63-71. doi:10.1016/j.parkreldis.2020.05.001
41. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of Gastroenterology. Clinical guideline: management of gastroparesis. *Am J Gastroenterol*. 2013;108(1):18-37; quiz 38. doi:10.1038/ajg.2012.373
42. Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F. Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. *Clin Nucl Med*. 2017;42(2):83-87. doi:10.1097/RLU.0000000000001470
43. Levein NG, Thörn SE, Wattwil M. Dopamine delays gastric emptying and prolongs oro-caecal transit time in volunteers. *Eur J Anaesthesiol*. 1999;16(4):246-250. doi:10.1046/j.1365-2346.1999.00471.x
44. Robertson DR, Renwick AG, Macklin B, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. *Eur J Clin Pharmacol*. 1992;42(4):409-412. doi:10.1007/BF00280127
45. Su A, Gandhi R, Barlow C, Triadafilopoulos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson's disease who present with functional gastrointestinal symptoms. *BMJ Open Gastroenterol*. 2017;4(1):e000132. doi:10.1136/bmjgast-2017-000132
46. Warren Olanow C, Torti M, Kieburz K, et al. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: a pharmacokinetics, safety, and efficacy study. *Mov Disord*. 2019;34(3):425-429. doi:10.1002/mds.27610
47. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. *Clin Neuropharmacol*. 2006;29(2):61-67. doi:10.1097/00002826-200603000-00001
48. Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. *J Neurol Sci*. 2012;319(1-2):86-88. doi:10.1016/j.jns.2012.05.010
49. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. *Neurology*. 1996;46(4):1051-1054. doi:10.1212/wnl.46.4.1051
50. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology*. 2017;153(2):420-429. doi:10.1053/j.gastro.2017.04.022
51. Dardiotis E, Tsouris Z, Mentis AFA, et al. *H. pylori* and Parkinson's disease: meta-analyses including clinical severity. *Clin Neurol Neurosurg*. 2018;175:16-24. doi:10.1016/j.clineuro.2018.09.039
52. Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: association of *Helicobacter pylori* infection with Parkinson's diseases. *Helicobacter*. 2017;22(5). doi:10.1111/hel.12398
53. Zhong R, Chen Q, Zhang X, Li M, Lin W. *Helicobacter pylori* infection is associated with a poor response to levodopa in patients with Parkinson's disease: a systematic review and meta-analysis. *J Neurol*. 2022;269(2):703-711. doi:10.1007/s00415-021-10473-1
54. Pierantozzi M, Pietroiusti A, Sancesario G, et al. Reduced L-dopa absorption and increased clinical fluctuations in *Helicobacter pylori*-infected Parkinson's disease patients. *Neurol Sci*. 2001;22(1):89-91. doi:10.1007/s100720170061
55. Pierantozzi M, Pietroiusti A, Galante A, et al. *Helicobacter pylori*-induced reduction of acute levodopa absorption in Parkinson's disease patients. *Ann Neurol*. 2001;50(5):686-687. doi:10.1002/ana.1267
56. Pierantozzi M, Pietroiusti A, Brusa L, et al. *Helicobacter pylori* eradication and L-dopa absorption in patients with PD and motor fluctuations. *Neurology*. 2006;66(12):1824-1829. doi:10.1212/01.wnl.0000221672.01272.ba
57. Narożańska E, Biańska M, Adamiak-Giera U, et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of *Helicobacter pylori* infection. *Clin Neuropharmacol*. 2014;37(4):96-99. doi:10.1097/WNF.000000000000037
58. Tan AH, Lim SY, Mahadeva S, et al. *Helicobacter pylori* eradication in Parkinson's disease: a randomized placebo-controlled trial. *Mov Disord*. 2020;35(12):2250-2260. doi:10.1002/mds.28248
59. Mridula KR, Borgohain R, Chandrasekhar Reddy V, Bandaru VCS, Suryaprabha T. Association of *Helicobacter pylori* with Parkinson's disease. *J Clin Neurol Seoul Korea*. 2017;13(2):181-186. doi:10.3988/jcn.2017.13.2.181
60. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and *Helicobacter pylori* in Parkinson's disease. *J Neurol*. 2013;260(12):2974-2980. doi:10.1007/s00415-013-7089-6
61. Dobbs SM, Charlett A, Dobbs RJ, et al. Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following *Helicobacter pylori* eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. *Helicobacter*. 2013;18(3):187-196. doi:10.1111/hel.12035
62. Hashim H, Azmin S, Razlan H, et al. Eradication of *Helicobacter pylori* infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. *PLoS One*. 2014;9(11):e112330. doi:10.1371/journal.pone.0112330
63. Tan AH, Mahadeva S, Marras C, et al. *Helicobacter pylori* infection is associated with worse severity of Parkinson's disease. *Parkinsonism Relat Disord*. 2015;21(3):221-225. doi:10.1016/j.parkreldis.2014.12.009
64. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. *Helicobacter pylori* infection and motor fluctuations in patients with Parkinson's disease. *Mov Disord*. 2008;23(12):1696-1700. doi:10.1002/mds.22190
65. Liu H, Su W, Li S, et al. Eradication of *Helicobacter pylori* infection might improve clinical status of patients with Parkinson's disease, especially on bradykinesia. *Clin Neurol Neurosurg*. 2017;160:101-104. doi:10.1016/j.clineuro.2017.07.003
66. Lolekha P, Sriphanom T, Vilaichone RK. *Helicobacter pylori* eradication improves motor fluctuations in advanced Parkinson's disease patients: a prospective cohort study (HP-PD trial). *PLoS One*. 2021;16(5):e0251042. doi:10.1371/journal.pone.0251042
67. Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in Parkinson's disease. *Expert Opin Drug Metab Toxicol*. 2008;4(2):193-203. doi:10.1517/17425255.4.2.193
68. Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. *Clin Neuropharmacol*. 1990;13(1):19-28. doi:10.1097/00002826-199002000-00002

69. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. *N Engl J Med*. 1984;310(8):483-488. doi:10.1056/NEJM198402233100802
70. Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. *Clin Neuropharmacol*. 1987;10(6):527-537. doi:10.1097/00002826-198712000-00004
71. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. *Eur J Clin Pharmacol*. 1998;54(4):303-308. doi:10.1007/s002280050464
72. Carter JH, Nutt JG, Woodward WR, Hatcher LF, Trotman TL. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. *Neurology*. 1989;39(4):552-556. doi:10.1212/wnl.39.4.552
73. Tsui JK, Ross S, Poulin K, et al. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. *Neurology*. 1989;39(4):549-552. doi:10.1212/wnl.39.4.549
74. Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. *N Engl J Med*. 1975;292(4):181-184. doi:10.1056/NEJM197501232920404
75. Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. *J Clin Mov Disord*. 2016;3:8. doi:10.1186/s40734-016-0036-9
76. Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN. Dietary influences on the antiparkinsonian response to levodopa. *Arch Neurol*. 1987;44(10):1003-1005. doi:10.1001/archneur.1987.00520220009006
77. Wang L, Xiong N, Huang J, et al. Protein-restricted diets for ameliorating motor fluctuations in Parkinson's disease. *Front Aging Neurosci*. 2017;9:206. doi:10.3389/fnagi.2017.00206
78. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. *Gastroenterology*. 1984;86(6):1592-1610.
79. Joint FAO/WHO/UNU Expert Consultation on Protein and Amino Acid Requirements in Human Nutrition. *Protein and Amino Acid Requirements in Human Nutrition: Report of a Joint FAO/WHO/UNU Expert Consultation*. World Health Organization; 2007 Accessed September 26, 2022. <https://apps.who.int/iris/handle/10665/43411>
80. Leta V, Ray Chaudhuri K, Milner O, et al. Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: a systematic review of preclinical and clinical evidence. *Brain Behav Immun*. 2021;98:59-73. doi:10.1016/j.bbi.2021.07.026
81. Nishiwaki H, Ito M, Ishida T, et al. Meta-analysis of gut dysbiosis in Parkinson's disease. *Mov Disord*. 2020;35(9):1626-1635. doi:10.1002/mds.28119
82. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. *Science*. 2019;364(6445):eaau6323. doi:10.1126/science.aau6323
83. van Kessel SP, Auvinen P, Scheperjans F, El Aidy S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinson's disease. *NPJ Park Dis*. 2021;7(1):115. doi:10.1038/s41531-021-00260-0
84. Yamanishi Y, Choudhury ME, Yoshida A, et al. Impact of intestinal bacteria on levodopa pharmacokinetics in LCIG therapy. *Mov Disord Clin Pract*. 2022;9(3):362-368. doi:10.1002/mdc3.13417
85. Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. *NPJ Park Dis*. 2022;8(1):56. doi:10.1038/s41531-022-00321-y
86. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. *Parkinsonism Relat Disord*. 2014;20(5):535-540. doi:10.1016/j.parkreldis.2014.02.019
87. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord*. 2011;26(5):889-892. doi:10.1002/mds.23566
88. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord*. 2013;28(9):1241-1249. doi:10.1002/mds.25522
89. Fasano A, Liu LWC, Poon YY, Lang AE. Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model. *Mov Disord*. 2015;30(4):598-599. doi:10.1002/mds.26195
90. Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Mov Disord*. 2006;21(7):916-923. doi:10.1002/mds.20844
91. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. *J Neurol*. 2013;260(5):1332-1338. doi:10.1007/s00415-012-6801-2
92. Staisch J, Bakis G, Nutt J. A wrinkle in ON-time—a GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study. *Parkinsonism Relat Disord*. 2018;50:130-131. doi:10.1016/j.parkreldis.2018.02.021
93. Kellow JE, Gill RC, Wingate DL. Modulation of human upper gastrointestinal motility by rectal distension. *Gut*. 1987;28(7):864-868. doi:10.1136/gut.28.7.864
94. Boccia G, Buonavolontà R, Coccorullo P, Manguso F, Fuiano L, Staiano A. Dyspeptic symptoms in children: the result of a constipation-induced cologastric brake? *Clin Gastroenterol Hepatol*. 2008;6(5):556-560. doi:10.1016/j.cgh.2008.01.001
95. Nagayama H, Kajimoto Y, Kumagai T, Nishiyama Y, Mishina M, Kimura K. Pharmacokinetics of levodopa before and after gastrointestinal resection in Parkinson's disease. *Case Rep Neurol*. 2015;7(3):181-185. doi:10.1159/000381181
96. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. *Expert Rev Neurother*. 2006;6(10):1403-1411. doi:10.1586/14737175.6.10.1403
97. Miyae N, Yabe H, Nagai M, Nomoto M. Gastrointestinal surgical procedures affect levodopa pharmacokinetics in Parkinson's disease. *Parkinsonism Relat Disord*. 2020;76:29-31. doi:10.1016/j.parkreldis.2020.05.040
98. Miyae N, Yabe H, Nagai M. Gastrointestinal surgery improved the absorption of levodopa in Parkinson's disease. *Parkinsonism Relat Disord*. 2021;87:20-21. doi:10.1016/j.parkreldis.2021.04.009
99. Feldman S, Putcha L. Effect of anti-parkinsonism drugs on gastric emptying and intestinal transit in the rat. *Pharmacology*. 1977;15(6):503-511. doi:10.1159/000136728
100. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. *Clin Pharmacokinet*. 2002;41(4):261-309. doi:10.2165/0003088-200241040-00003
101. Alhassen S, Senel M, Alachkar A. Surface plasmon resonance identifies high-affinity binding of L-DOPA to siderocalin/lipocalin-2 through iron-siderophore action: implications for Parkinson's disease treatment. *ACS Chem Neurosci*. 2022;13(1):158-165. doi:10.1021/acscchemneuro.1c00693
102. van der Heide F. Acquired causes of intestinal malabsorption. *Best Pract Res Clin Gastroenterol*. 2016;30(2):213-224. doi:10.1016/j.bpg.2016.03.001
103. Effinger A, O'Driscoll CM, McAllister M, Fotaki N. Impact of gastrointestinal disease states on oral drug absorption—implications for formulation design—a PEARRL review. *J Pharm Pharmacol*. 2019;71(4):674-698. doi:10.1111/jphp.12928
104. Bayer AJ, Day JJ, Finucane P, Pathy MS. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. *J Clin*

- Pharm Ther.* 1988;13(3):191-194. doi:10.1111/j.1365-2710.1988.tb00179.x
105. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. *Clin Neuropharmacol.* 1999;22(6):351-355.
 106. Nagayama H, Hamamoto M, Ueda M, Nito C, Yamaguchi H, Katayama Y. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. *Clin Neuropharmacol.* 2004;27(6):270-273. doi:10.1097/01.wnf.0000150865.21759.bc
 107. Miyaue N, Kubo M, Nagai M. Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide. *Brain Behav.* 2022;12(7):e2672. doi:10.1002/brb3.2672
 108. Leta V, Dafsari HS, Sauerbier A, et al. Personalised advanced therapies in Parkinson's disease: the role of non-motor symptoms profile. *J Pers Med.* 2021;11(8):773. doi:10.3390/jpm11080773
 109. Arai E, Arai M, Uchiyama T, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. *Brain J Neurol.* 2012;135(Pt 5):1478-1485. doi:10.1093/brain/aws086
 110. Dafsari HS, Martinez-Martin P, Rizo A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. *Mov Disord.* 2019;34(3):353-365. doi:10.1002/mds.27626
 111. Fasano A, Gurevich T, Jech R, et al. Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the cosmos study. *Mov Disord.* 2021;36(8):1853-1862. doi:10.1002/mds.28596

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Leta V, Klingelhofer L, Longardner K, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. *Eur J Neurol.* 2023;30:1465-1480. doi:10.1111/ene.15734